As the fourth and largest comparative trial, the ONTARGET study confirms, beyond doubt, that angiotensin-receptor blockers (ARBs) are not better than angiotensin-converting–enzyme (ACE) inhibitors at reducing fatal and nonfatal cardiovascular events.
Prof. John McMurray - Cardiologist, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland
Hat tip: IN VIVO
2 comments:
Oh Goodness! Micardis results with OnTarget fell Mostly OffTarget! What will you do now?
Just saying.
They got what was coming to them. They are a crooked outfit.
I took lisinopril for over 6 months and then started having episodes of waking up in the middle of the night feeling as if I had to force myself to start breathing. I switched to Tekturna, and the very first night, it happened again. Now I take a calcium channel blocker, Verapimil. Any more, I'm almost afraid to take any drugs. My doc wants me to take a statin, but I refuse. I'm beginning to think the body is almost like a wayward child. It wants to be the way it is. When you change things through pharmaceuticals, the body fights back.
Post a Comment